for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.AS

Latest Trade

146.85EUR

Change

1.60(+1.10%)

Volume

381,286

Today's Range

144.35

 - 

146.85

52 Week Range

74.48

 - 

171.20

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
145.25
Open
144.90
Volume
381,286
3M AVG Volume
8.86
Today's High
146.85
Today's Low
144.35
52 Week High
171.20
52 Week Low
74.48
Shares Out (MIL)
54.82
Market Cap (MIL)
8,954.97
Forward P/E
-32.21
Dividend (Yield %)
--

Next Event

Galapagos NV at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Pharnext Updates On Collaboration with Galapagos

Galapagos Files Application To Initiate Insolvency Proceedings

BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Industry

Biotechnology & Drugs

Contact Info

Generaal De Wittelaan 3

+32.15.342900

http://www.glpg.com

Executive Leadership

Onno van de Stolpe

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Rajesh B. Parekh

Non-Executive Chairman of the Board

Bart Filius

Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer

Piet Wigerinck

Member of the Executive Committee, Chief Scientific Officer

Walid Abi-Saab

Member of the Executive Committee, Chief Medical Officer

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.2K

2018

0.3K

2019(E)

0.2K
EPS (EUR)

2016

1.180

2017

-2.340

2018

-0.560

2019(E)

-4.471
Price To Earnings (TTM)
--
Price To Sales (TTM)
27.60
Price To Book (MRQ)
6.96
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.24
LT Debt To Equity (MRQ)
1.79
Return on Investment (TTM)
-6.22
Return on Equity (TTM)
-5.16

Latest News

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN

CORRECTED-BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings

* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion (£4.06 billion) in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.

Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report

Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Shares in Galapagos jump 15 percent after arthritis drug results

Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

BRIEF-Galapagos FY Revenue Up At 317.8 Million Euros

* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

Rheinmetall <RHMG.DE> on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

BRIEF-Galapagos Reports Top-line Interim Results Of FALCON Trial Part 1 In CF

* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF

BRIEF-Galapagos 9-Month Revenue Rises To 205.1 Million Euros

* REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

BRIEF-Galapagos: Capital Increase Of EUR 2.0 Million

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

Galapagos, Gilead bask in $4-6 billion new drug sales hope

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos <GLPG.AS> to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

Galapagos shares soar on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

BRIEF-Galapagos NV reports H1 Group Revenues Of €101.9 Million

* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up